Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

RxSight (RXST) EBIAT (2020 - 2026)

RxSight filings provide 6 years of EBIAT readings, the most recent being -$9.2 million for Q4 2025.

  • On a quarterly basis, EBIAT fell 54.13% to -$9.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$38.9 million, a 41.85% decrease, with the full-year FY2025 number at -$38.9 million, down 41.85% from a year prior.
  • EBIAT hit -$9.2 million in Q4 2025 for RxSight, up from -$9.8 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of -$5.9 million in Q4 2024 to a low of -$17.6 million in Q1 2022.
  • Median EBIAT over the past 5 years was -$12.1 million (2023), compared with a mean of -$11.5 million.
  • Biggest five-year swings in EBIAT: crashed 159.84% in 2021 and later skyrocketed 55.96% in 2024.
  • RxSight's EBIAT stood at -$15.7 million in 2021, then grew by 0.79% to -$15.6 million in 2022, then skyrocketed by 41.21% to -$9.2 million in 2023, then soared by 35.29% to -$5.9 million in 2024, then tumbled by 54.13% to -$9.2 million in 2025.
  • The last three reported values for EBIAT were -$9.2 million (Q4 2025), -$9.8 million (Q3 2025), and -$11.8 million (Q2 2025) per Business Quant data.